Testing the Combination of XL184 (Cabozantinib), Nivolumab, and Ipilimumab for Poorly Differentiated Neuroendocrine Tumors
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Institutes of Health Clinical Center (CC)
Crinetics Pharmaceuticals Inc.
Boston Scientific Corporation
University of Florida
Ohio State University Comprehensive Cancer Center
University of Iowa
University of Miami
Tanabe Pharma America, Inc.
Wren Laboratories LLC
National Institutes of Health Clinical Center (CC)
Case Comprehensive Cancer Center
National Institutes of Health Clinical Center (CC)
Turning Point Therapeutics, Inc.
Hoffmann-La Roche
University of Roma La Sapienza
Jagiellonian University
CHU de Quebec-Universite Laval
Rigshospitalet, Denmark
European Institute of Oncology
Catholic University of the Sacred Heart
Rigshospitalet, Denmark
Asan Medical Center
Fundación de investigación HM
Johannes Gutenberg University Mainz
Peking Union Medical College Hospital
European Institute of Oncology
AIO-Studien-gGmbH
National Institutes of Health Clinical Center (CC)
Yale University
Vanderbilt-Ingram Cancer Center
H. Lee Moffitt Cancer Center and Research Institute
Ochsner Health System
Novartis
University of Turin, Italy